The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Safety and efficacy of sabatolimab plus azacitidine or decitabine in patients with HR-MDS and AML
In this video, Andrew M. Brunner, MD, Massachusetts General Hospital, Boston, MA, summarizes some findings from an analysis of a Phase Ib study which aimed to investigate the use of sabatolimab, a TIM-3 targeted monoclonal antibody, in combination with azacitidine or decitabine in the treatment of patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS) (NCT03066648). Dr Brunner first discusses the role of TIM-3 in immune response to malignant cells, and the mechanism of action of sabatolimab as an inhibitor of TIM-3. Dr Brunner then reports on some of the results of this study, including immune-related adverse events and response rates, and explains that these preliminary results are very encouraging for the use of sabatolimab in the treatment of MDS and AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
Disclosures
Celgene, Forty Seven Inc, Jazz: Other: Advisory Board; Novartis, Celgene, Takeda, AstraZeneca: Research Funding.
